150 related articles for article (PubMed ID: 16507988)
21. MNT inhibits the migration of human hepatocellular carcinoma SMMC7721 cells.
Wu J; Zhou Q; Wang Y; Zhou X; Li J
Biochem Biophys Res Commun; 2012 Feb; 418(1):93-7. PubMed ID: 22244890
[TBL] [Abstract][Full Text] [Related]
22. MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis.
Nguyen HV; Vandenberg CJ; Robati MR; Ng AP; Cory S
Cell Death Differ; 2023 Apr; 30(4):1018-1032. PubMed ID: 36755068
[TBL] [Abstract][Full Text] [Related]
23. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis.
Schmidt T; Karsunky H; Gau E; Zevnik B; Elsässer HP; Möröy T
Oncogene; 1998 Nov; 17(20):2661-7. PubMed ID: 9840930
[TBL] [Abstract][Full Text] [Related]
24. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
Lüscher B; Larsson LG
Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
[TBL] [Abstract][Full Text] [Related]
25. Myc, Max, and Mnt: molecular mechanisms of enhancement of cholangiocarcinogenesis by cholestasis.
Nakamura I; Roberts LR
Gastroenterology; 2011 Jul; 141(1):32-4. PubMed ID: 21620848
[No Abstract] [Full Text] [Related]
26. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
[TBL] [Abstract][Full Text] [Related]
27. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.
Yang W; Shen J; Wu M; Arsura M; FitzGerald M; Suldan Z; Kim DW; Hofmann CS; Pianetti S; Romieu-Mourez R; Freedman LP; Sonenshein GE
Oncogene; 2001 Mar; 20(14):1688-702. PubMed ID: 11313917
[TBL] [Abstract][Full Text] [Related]
28. OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival.
Vasilevsky NA; Ruby CE; Hurlin PJ; Weinberg AD
Eur J Immunol; 2011 Apr; 41(4):1024-34. PubMed ID: 21400495
[TBL] [Abstract][Full Text] [Related]
29. Mad1 is a transcriptional repressor of Bcl-6.
Lee SC; Bottaro A; Chen L; Insel RA
Mol Immunol; 2006 May; 43(12):1965-71. PubMed ID: 16423395
[TBL] [Abstract][Full Text] [Related]
30. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
Gupta K; Anand G; Yin X; Grove L; Prochownik EV
Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
[TBL] [Abstract][Full Text] [Related]
31. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
32. Cooperation of Gata3, c-Myc and Notch in malignant transformation of double positive thymocytes.
van Hamburg JP; de Bruijn MJ; Dingjan GM; Beverloo HB; Diepstraten H; Ling KW; Hendriks RW
Mol Immunol; 2008 Jun; 45(11):3085-95. PubMed ID: 18471881
[TBL] [Abstract][Full Text] [Related]
33. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
[TBL] [Abstract][Full Text] [Related]
34. STAT6 deletion converts the Th2 inflammatory pathology afflicting Lat(Y136F) mice into a lymphoproliferative disorder involving Th1 and CD8 effector T cells.
Archambaud C; Sansoni A; Mingueneau M; Devilard E; Delsol G; Malissen B; Malissen M
J Immunol; 2009 Mar; 182(5):2680-9. PubMed ID: 19234162
[TBL] [Abstract][Full Text] [Related]
35. Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymus.
Patel DR; Li W; Park JS; Sofi MH; Gourley TS; Hangoc G; Kaplan MH; Chang CH
Cell Immunol; 2005 Jan; 233(1):30-40. PubMed ID: 15876426
[TBL] [Abstract][Full Text] [Related]
36. An internal ribosome entry segment in the 5' untranslated region of the mnt gene.
Stoneley M; Spencer JP; Wright SC
Oncogene; 2001 Feb; 20(7):893-7. PubMed ID: 11314024
[TBL] [Abstract][Full Text] [Related]
37. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
38. Fas-independent apoptosis in T-cell tumours induced by the CD2-myc transgene.
Cameron ER; Morton J; Johnston CJ; Irvine J; Bell M; Onions DE; Neil JC; Campbell M; Blyth K
Cell Death Differ; 2000 Jan; 7(1):80-8. PubMed ID: 10713723
[TBL] [Abstract][Full Text] [Related]
39. Modulation of T-lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad1.
Iritani BM; Delrow J; Grandori C; Gomez I; Klacking M; Carlos LS; Eisenman RN
EMBO J; 2002 Sep; 21(18):4820-30. PubMed ID: 12234922
[TBL] [Abstract][Full Text] [Related]
40. Molecular analysis of a Myc antagonist, ROX/Mnt, at 17p13.3 in human lung cancers.
Takahashi T; Konishi H; Kozaki K; Osada H; Saji S; Takahashi T; Takahashi T
Jpn J Cancer Res; 1998 Apr; 89(4):347-51. PubMed ID: 9617337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
